Seven Bridges

Seven Bridges is the biomedical data analysis company accelerating breakthroughs in genomics research for cancer, drug development and precision medicine. We democratize genomics by enabling researchers anywhere to process and understand genomic data faster and more efficiently than ever, at any scale.
 
Thousands of researchers in government, biotech, pharmaceutical and academic labs use Seven Bridges, including three of the largest genomics projects in the world:
 
·         The Cancer Genomics Cloud (CGC), powered by Seven Bridges, is one of three pilot systems funded by the National Cancer Institute to explore the paradigm of colocalizing massive genomics datasets, alongside secure and scalable computational resources to analyze them. Seven Bridges was honored with Bio-IT World Best of Show Award 2016 for Cancer Genomics Cloud. (http://www.cancergenomicscloud.org/)

·         We collaborate with U.S. Department of Veteran Affairs to develop analytic and hybrid cloud initiatives for Million Veteran Program. (http://www.research.va.gov/mvp/)
 
·         Genomics England partnered with Seven Bridges to analyze data from the 100,000 Genomes project. (http://www.sbgenomics.co.uk/)

Our biomedical data analysis platform will be used by the Cancer Moonshot’s Blood Profiling Atlas project, designed to accelerate the development and approval of simple, accurate, and reliable blood tests for cancer diagnosis and precision treatment.

As the NIH’s only commercial Trusted Partner, Seven Bridges authenticates and authorizes access to one of the world’s largest cancer genomics dataset. (https://gds.nih.gov/02dr2.html)

Seven Bridges has been recognized by the MIT Technology Review as one of the Top 50 Smartest Companies in the World in 2016 (https://www.technologyreview.com/lists/companies/2016/intro/#seven-bridges).
Company offices are located in Cambridge, Mass., San Francisco, London, Belgrade, Istanbul and Ankara. We would love to have you join us advance genomics at our leading, well-funded, and dynamic startup.

·